Horsham, Pennsylvania, USA – April 22, 2026

In a major advancement for autoimmune neurology, Johnson & Johnson has reported long-term Phase 3 data demonstrating sustained disease control with IMAAVY® (nipocalimab-aahu) in patients with generalized myasthenia gravis (gMG). The findings, presented at the American Academy of Neurology (AAN) 2026 Meeting, highlight over two years of durable clinical efficacy, reduced immunoglobulin G (IgG) levels, and improved patient quality of life, reinforcing IMAAVY’s position as a leading FcRn-targeting therapy in this challenging autoimmune condition.

Sustained Clinical Efficacy and Long-Term Disease Control

Data from the Phase 3 Vivacity-MG3 study and ongoing open-label extension (OLE) demonstrated that IMAAVY delivers consistent and sustained improvements in disease severity over 120 weeks, one of the longest follow-up periods reported for therapies in Generalized Myasthenia Gravis. Patients showed mean reductions of 6.47 points in MG-ADL scores and 5.97 points in QMG scores, indicating significant improvements in daily function and muscle strength.

Importantly, approximately 50% of patients achieved minimal symptom expression (MSE), with nearly one-third maintaining sustained MSE for at least eight weeks, a key indicator of long-term disease stability. These outcomes reflect the therapy’s ability to provide durable symptom control, a critical goal in managing chronic autoimmune diseases where fluctuations in disease activity can significantly impact patient well-being.

Additionally, the study showed a greater than 64% reduction in total IgG levels, including pathogenic autoantibodies, confirming IMAAVY’s mechanism of action targeting FcRn pathways to reduce disease-driving antibodies while preserving essential immune function.

Advertisement

cGxPJobs Banner

Quality of Life Improvements and Reduced Treatment Burden

A post-hoc analysis from the study further revealed that patients achieving sustained minimal symptom expression experienced significantly greater improvements in quality of life, as measured by validated clinical scales. Patients treated with IMAAVY plus standard of care were four times more likely to reach sustained MSE compared to placebo, highlighting the therapy’s superior clinical benefit.

Beyond symptom control, IMAAVY demonstrated a notable reduction in corticosteroid use, with 57% of patients achieving low-dose steroid regimens, addressing a major concern associated with long-term steroid therapy, including adverse side effects and systemic complications.

These findings emphasize the importance of patient-centric treatment goals, where achieving sustained disease control translates into improved daily functioning, reduced healthcare burden, and enhanced overall quality of life.

Expanding Clinical Development and Future Outlook

Building on these promising results, Johnson & Johnson has initiated the EPIC study, the first head-to-head trial comparing IMAAVY with another FcRn blocker, signaling a new phase of competitive evaluation in the treatment landscape for gMG. This study aims to further validate IMAAVY’s efficacy, safety, and differentiation in a rapidly evolving therapeutic area.

IMAAVY is already approved for use in adult and pediatric patients aged 12 years and older with antibody-positive gMG, and ongoing research continues to explore its potential across multiple autoimmune indications, including rheumatologic and maternal-fetal diseases.

As the prevalence of autoimmune disorders continues to rise globally, therapies like IMAAVY represent a significant step forward in precision immunology, offering targeted approaches that address the underlying disease mechanisms rather than providing only symptomatic relief.

These latest findings reinforce Johnson & Johnson’s leadership in innovative medicine and autoimmune disease research, while highlighting the growing role of FcRn inhibitors in delivering long-term disease control and improved patient outcomes in chronic neuromuscular conditions.

Source: Johnson & Johnson press release